Clinical Scorecard: B antigen transfusions may raise allergy risk
At a Glance
Category
Detail
Condition
Allergic transfusion reactions (ATRs)
Key Mechanisms
Association of B or AB plasma or platelets with increased ATR risk in blood type O patients in high alpha-gal syndrome prevalence areas.
Target Population
Patients with blood type O receiving blood transfusions.
Care Setting
Academic medical centers in regions with varying alpha-gal syndrome prevalence.
Key Highlights
Patients with blood type O receiving B or AB products had 3.93 times the risk of ATRs in high-prevalence areas.
Moderate to severe ATRs were 9.14 times more likely for blood type O patients receiving B products in high-prevalence clusters.
No excess ATRs were observed in low-prevalence clusters for blood type O patients receiving B, AB, or A products.
Guideline-Based Recommendations
Diagnosis
Monitor for allergic transfusion reactions in patients receiving B or AB products, especially in high AGS prevalence areas.
Management
Consider evaluating local reaction patterns and approaches to reduce risk from B antigen-containing products.
Monitoring & Follow-up
Track and report allergic transfusion reactions to improve understanding of risks associated with B and AB products.
Risks
Increased risk of ATRs associated with B or AB products in blood type O patients in high AGS prevalence regions.
Patient & Prescribing Data
Patients with blood type O undergoing transfusions.
B and AB products are associated with higher ATR risks in specific geographic areas.
Clinical Best Practices
Clinicians should be aware of the potential for increased ATRs when transfusing B or AB products to blood type O patients in high AGS prevalence areas.
Encourage reporting of allergic transfusion reactions to enhance data collection and risk assessment.
Neighborhood vulnerability was associated with poorer survival among women with epithelial ovarian cancer, with a stronger association among Black women.
The assay is indicated to identify patients with advanced melanoma who have BRAF V600E or BRAF V600K variants and may benefit from FDA-approved targeted therapies.
